COVID-19News

Trivitron Healthcare develops diagnostic products to detect Omicron Variants BF.7 and XBB

Trivitron BIOCARD Pro COVID-19 Rapid Antigen Kit is an immunochromatography-based test that offers qualitative detection of specific antigens to COVID-19 present in the human nasopharyngeal swab

Medical devices company Trivitron Healthcare has developed and commercialised a wide range of diagnostic products, including VTM, RNA Extraction Kits, COVID-19 Rapid Antigen Test Kits, and COVID-19 RT- PCR test Kits for effective diagnosis of new variants of SARS-CoV-2. Trivitron’s R&D conducted an in-silico analysis of mutations of the SARS-CoV-2 virus, ensuring Trivitron’s COVID-19 testing kits can effectively detect the mutated strain variants, Omicron BF.7 and XBB.

“The new strain Omicron contains mutations in its Spike (S) protein. The in-silico analysis suggests that none of the mutations associated with these variants impact Trivitron COVID-19 test kits against the detection. They do not rely on the spike gene-based detection,” Dr Suresh Thakur, President – Scientific Affairs, Trivitron Healthcare.

Trivitron’s COVIDSure, COVIDSure PRO and COVIDsure Direct RT-PCR Kits detect the conserved region of SARS-CoV-2 and ORF1ab, Envelope E-gene, and Nucleocapsid N-gene. Mutation in the S gene associated with Omicron and other variants remains unaffected by this multiplex RT-PCR test. These kits can detect SARS-COV-2 variants, including Omicron BF.7 and XBB variants.

Trivitron BIOCARD Pro COVID-19 Rapid Antigen Kit is an immunochromatography-based test that offers qualitative detection of specific antigens to COVID-19 present in the human nasopharyngeal swab. This antigen test kit detects the conserved region of the N gene of SARS-CoV-2 that remains unaffected by the mutation in the S gene, hence can detect the Omicron variants BF.7 and XBB of COVID-19.

Chandra Ganjoo, Group CEO, Trivitron Healthcare, stated, “Trivitron is dedicated to providing cutting-edge technologies for improved disease/illness screening. We feel that the current situation requires acting quickly to stop the virus propagation because we are a responsible maker of MedTech goods. India has historically been at the forefront of the global humanitarian effort, especially during the COVID-19 pandemic, and at this time, the entire world needs assistance. Our Trivitron R&D team, scientists, and quality control department verify the tests by continuous literature review and in-silico analysis of the new circulating strains keeping in track the importance of effective and precise diagnosis for the masses.”

Support us in our endeavor to bring you Advertisement free content.
Choose your options to donate or subscribe.

Tags

Related Articles

Back to top button
Close
Close